Association of an APOC3 promoter variant with type 2 diabetes risk and need for insulin treatment in lean persons

[1]  Monique M. B. Breteler,et al.  The Rotterdam Study: 2016 objectives and design update , 2015, European Journal of Epidemiology.

[2]  H. Florez,et al.  Increased apolipoprotein C-III levels associated with insulin resistance contribute to dyslipidemia in normoglycemic and diabetic subjects from a triethnic population. , 2006, Atherosclerosis.

[3]  J. Hokanson,et al.  Susceptibility to type 1 diabetes is associated with ApoCIII gene haplotypes. , 2006, Diabetes.

[4]  J. Eriksson,et al.  Lipoprotein lipase activity/mass ratio is higher in omental than in subcutaneous adipose tissue , 2006, European journal of clinical investigation.

[5]  E. Cerasi,et al.  K-value and low insulin secretion in a non-obese white population: predicted glucose tolerance after 25 years , 2005, Diabetologia.

[6]  P. Poulsen,et al.  Heritability of insulin secretion, peripheral and hepatic insulin action, and intracellular glucose partitioning in young and old Danish twins. , 2005, Diabetes.

[7]  Nancy Dekki,et al.  Apolipoprotein CIII promotes Ca2+-dependent β cell death in type 1 diabetes , 2004 .

[8]  M. McCarthy,et al.  Heritability estimates for beta cell function and features of the insulin resistance syndrome in UK families with an increased susceptibility to Type 2 diabetes , 2004, Diabetologia.

[9]  P. Arner,et al.  Different aetiologies of Type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects , 1991, Diabetologia.

[10]  P. Demacker,et al.  Apolipoprotein C in Type 2 (non-insulin-dependent) diabetic patients with hypertriglyceridaemia , 1982, Diabetologia.

[11]  H. Jörnvall,et al.  Apolipoprotein CIII promotes Ca2+-dependent beta cell death in type 1 diabetes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[12]  L. Nyström,et al.  The Swedish childhood diabetes study — results from a nine year case register and a one year case-referent study indicating that Type 1 (insulin-dependent) diabetes mellitus is associated with both Type 2 (non-insulin-dependent) diabetes mellitus and autoimmune disorders , 2004, Diabetologia.

[13]  N. Wareham,et al.  Variants in the APOC3 promoter insulin responsive element modulate insulin secretion and lipids in middle-aged men. , 2003, Biochimica et biophysica acta.

[14]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[15]  J. Eriksson,et al.  Fetal origins of adult disease: strength of effects and biological basis. , 2002, International journal of epidemiology.

[16]  G. Fiestras-Janeiro,et al.  Glucose metabolism in lean patients with mild type 2 diabetes mellitus: evidence for insulin-sensitive and insulin-resistant variants. , 2002, Metabolism: clinical and experimental.

[17]  L. Groop,et al.  Possible human leukocyte antigen-mediated genetic interaction between type 1 and type 2 Diabetes. , 2001, Journal of Clinical Endocrinology and Metabolism.

[18]  K. Alberti,et al.  Variable effects of the APOC3 –482C > T variant on insulin, glucose and triglyceride concentrations in different ethnic groups , 2001, Diabetologia.

[19]  L. Groop,et al.  Consequences of a family history of type 1 and type 2 diabetes on the phenotype of patients with type 2 diabetes. , 2000, Diabetes care.

[20]  L. Groop,et al.  Insulin sensitivity and insulin secretion in monozygotic and dizygotic twins , 2000, Diabetologia.

[21]  I. Goldberg,et al.  Circulating Lipoprotein Profiles are Modulated Differently by Lipoprotein Lipase in Obese Humans , 2000, Journal of cardiovascular risk.

[22]  J. Ribalta,et al.  ApoCIII gene variants modulate postprandial response to both glucose and fat tolerance tests. , 1999, Circulation.

[23]  L. Havekes,et al.  Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[24]  J. Neel.  Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? 1962. , 1999, Bulletin of the World Health Organization.

[25]  J. McGarry,et al.  Fatty acids, lipotoxicity and insulin secretion , 1999, Diabetologia.

[26]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[27]  M. Fantone,et al.  Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus , 1997, Diabetes Care.

[28]  J. Seidell.  Time Trends in Obesity: An Epidemiological Perspective , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[29]  G. Boden.  Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM , 1997, Diabetes.

[30]  G. Boden,et al.  Fatty acids and insulin resistance. , 1998, Diabetes care.

[31]  G. Bray,et al.  Health hazards of obesity. , 1996, Endocrinology and metabolism clinics of North America.

[32]  J. Breslow,et al.  Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. , 1995, The Journal of clinical investigation.

[33]  T. Kuzuya,et al.  Relationship between obesity and concordance rate for type 2 (non-insulin-dependent) diabetes mellitus among twins. , 1994, Diabetes research and clinical practice.

[34]  S. B. Pedersen,et al.  Characterization of regional and gender differences in glucocorticoid receptors and lipoprotein lipase activity in human adipose tissue. , 1994, The Journal of clinical endocrinology and metabolism.

[35]  C. Russell,et al.  Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese women and men. , 1993, The Journal of clinical investigation.

[36]  J. Breslow,et al.  An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Mozzoli,et al.  Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. , 1991, The Journal of clinical investigation.

[38]  T. W. Haeften,et al.  Decreased insulin secretory capacity and normal pancreatic B‐cell glucose sensitivity in non‐obese patients with NIDDM , 1991, European journal of clinical investigation.

[39]  E. Cerasi,et al.  DIABETES MELLITUS , 1924, Nihon rinsho. Japanese journal of clinical medicine.

[40]  W. Irvine,et al.  CLINICAL AND PATHOGENIC SIGNIFICANCE OF PANCREATIC-ISLET-CELL ANTIBODIES IN DIABETICS TREATED WITH ORAL HYPOGLYCÆMIC AGENTS , 1977, The Lancet.

[41]  Simpson Ca.  ADAPTATION TO THE DESERT. , 1964 .

[42]  J. Neel.  Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? , 1962, American journal of human genetics.